Two study drugs before surgery for early high-risk breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two study drugs given before surgery to shrink early-stage, high-risk hormone-positive breast cancer. The goal is to see if this approach can help reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70.
- You have been diagnosed with invasive breast cancer and have not yet had any treatment for it.
- You are generally well and able to do your daily activities (ECOG 0–1).
- Your cancer is hormone receptor positive (ER+) and HER2 negative.
- Your tumor is at least 2 cm, or has spread to nearby lymph nodes, and is considered high-risk (grade 2 or 3).
- You have not had other cancers in the last 5 years, except for certain very early skin or cervical cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Hear when a new ER+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.